Efficacy of antidepressants in juvenile depression: meta-analysis

Background The safety of antidepressants in children and adolescents is being questioned and the efficacy of these drugs in juvenile depression remains uncertain Aims To assess antidepressant efficacy in juvenile depression Method Systematic review and meta-analysis of randomised controlled trials (RCTs) comparing responses to antidepressants, overall and by type, v. placebo in young people with depression Results Thirty drug-placebo contrasts in RCTs lasting 8 weeks (median) involved 3069 participants (512 person-years) of average age 13.5 years. Meta-analysis yielded a modest pooled drug/placebo response rate ratio (RR=1.22, 95% CI 1.15–1.31), with little separation between antidepressant types. Findings were similar for response rate differences and corresponding number needed to treat (NNT): overall NNT=9; tricyclic antidepressants NNT=14 > serotonin reuptake inhibitors NNT=9 > other antidepressants NNT=8. Numbers needed to treat decreased with increasing age: children (NNT=21) > mixed ages (NNT=10) > adolescents (NNT=8) Conclusions Antidepressants of all types showed limited efficacy in juvenile depression, but fluoxetine might be more effective, especially in adolescents. Studies in children and in severely depressed, hospitalised or suicidal juvenile patients are needed, and effective, safe and readily accessible treatments for juvenile depression are urgently required

[1]  David Brent,et al.  Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[2]  Elaine H Morrato,et al.  Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. , 2007, The American journal of psychiatry.

[3]  Andrew C Leon,et al.  Expanding the black box - depression, antidepressants, and the risk of suicide. , 2007, The New England journal of medicine.

[4]  D. Brent,et al.  Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. , 2007, The American journal of psychiatry.

[5]  Harold Alan Pincus,et al.  Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. , 2007, JAMA.

[6]  Robert L Findling,et al.  Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[7]  M. Olfson,et al.  Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study. , 2006, Archives of general psychiatry.

[8]  F. Goodwin,et al.  ACNP Task Force Report on SSRIs and Suicidal Behavior in Youth , 2006, Neuropsychopharmacology.

[9]  R. Baldessarini,et al.  Suicidal risk in antidepressant drug trials. , 2006, Archives of general psychiatry.

[10]  J. Racoosin,et al.  Suicidality in pediatric patients treated with antidepressant drugs. , 2006, Archives of general psychiatry.

[11]  A. Raz.  Perspectives on the Efficacy of Antidepressants for Child and Adolescent Depression , 2005, PLoS medicine.

[12]  J. Jureidini,et al.  Wishful thinking: antidepressant drugs in childhood depression. , 2005, The British journal of psychiatry : the journal of mental science.

[13]  G. Emslie,et al.  Review of the efficacy and safety of antidepressants in youth depression. , 2005, Journal of child psychology and psychiatry, and allied disciplines.

[14]  R. Baldessarini,et al.  Risk of mania with antidepressants. , 2005, Archives of pediatrics & adolescent medicine.

[15]  K. Walker.  Rethinking childhood depression , 2005, BMJ : British Medical Journal.

[16]  T. Newman.  A black-box warning for antidepressants in children? , 2004, The New England journal of medicine.

[17]  D. Courtney.  Selective Serotonin Reuptake Inhibitor and Venlafaxine Use in Children and Adolescents with Major Depressive Disorder: A Systematic Review of Published Randomized Controlled Trials , 2004, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[18]  R. Findling,et al.  A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. , 2004, The American journal of psychiatry.

[19]  Peter Fonagy,et al.  Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data , 2004, The Lancet.

[20]  M. Haby,et al.  Efficacy and safety of antidepressants for children and adolescents , 2004, BMJ : British Medical Journal.

[21]  A. Gelenberg,et al.  Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. , 2004, Psychiatric services.

[22]  M. Rynn,et al.  Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. , 2003, JAMA.

[23]  M. Detke,et al.  Placebo Response and Antidepressant Clinical Trial Outcome , 2003, The Journal of nervous and mental disease.

[24]  J. Biederman,et al.  Fluoxetine Pharmacokinetics in Pediatric Patients , 2002, Journal of clinical psychopharmacology.

[25]  K. Wagner,et al.  Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[26]  N. Ryan,et al.  Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[27]  D. Charney,et al.  Are child-, adolescent-, and adult-onset depression one and the same disorder? , 2001, Biological Psychiatry.

[28]  B. Birmaher,et al.  Biological studies in depressed children and adolescents. , 2001, The international journal of neuropsychopharmacology.

[29]  A. Hrõbjartsson,et al.  Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. , 2001, The New England journal of medicine.

[30]  I. Olkin,et al.  Improving the quality of reports of meta‐analyses of randomised controlled trials: the QUOROM statement , 2000, Revista espanola de salud publica.

[31]  R. Anton,et al.  A double‐blind, placebo‐controlled trial of sertraline in depressed adolescent alcoholics: a pilot study , 2000, Human psychopharmacology.

[32]  F. Lynch,et al.  Trends in the prescribing of psychotropic medications to preschoolers. , 2000, JAMA.

[33]  C Cates,et al.  Confidence intervals for the number needed to treat , 1999 .

[34]  R. Harrington,et al.  Systematic review of efficacy of cognitive behaviour therapies in childhood and adolescent depressive disorder , 1998, BMJ.

[35]  N. Ryan,et al.  Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[36]  D. McIntire,et al.  Psychiatric illness and family support in children and adolescents with diabetic ketoacidosis: a controlled study. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[37]  A. Rush,et al.  A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. , 1997, Archives of general psychiatry.

[38]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[39]  G. Sethuraman,et al.  Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial. , 1997, The American journal of psychiatry.

[40]  J. Fawcett,et al.  Efficacy issues with antidepressants. , 1997, The Journal of clinical psychiatry.

[41]  R. Baldessarini,et al.  Predicting desipramine levels in children and adolescents: a naturalistic clinical study. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[42]  M. McGee.  Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. , 1997, The Journal of clinical psychiatry.

[43]  N. Ryan,et al.  Childhood and adolescent depression: a review of the past 10 years. Part I. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[44]  N. Ryan,et al.  A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[45]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[46]  P. Hazell,et al.  Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis , 1995, BMJ.

[47]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[48]  J. Szalai,et al.  Response to desipramine treatment in adolescent depression: a fixed-dose, placebo-controlled trial. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.

[49]  V. F. Dinicola,et al.  Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up , 1990, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[50]  G. Bernstein,et al.  Comparative studies of pharmacotherapy for school refusal. , 1990, Journal of the American Academy of Child and Adolescent Psychiatry.

[51]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[52]  T. Petti,et al.  Imipramine treatment of depressed children: a double-blind pilot study. , 1982, Journal of clinical psychopharmacology.

[53]  R. Feiguine,et al.  Clinical effects of amitriptyline in adolescent depression. A pilot study. , 1981, Journal of the American Academy of Child Psychiatry.

[54]  J. Stockman.  Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment: A Meta-analysis of Randomized Controlled Trials , 2009 .

[55]  F. Degruy,et al.  Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. , 2008, The American journal of psychiatry.

[56]  S. Bhatia,et al.  Childhood and adolescent depression. , 2007, American family physician.

[57]  Richard M Glass,et al.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. , 2005, The Journal of pediatrics.

[58]  L. Magder,et al.  Psychotropic practice patterns for youth: a 10-year perspective. , 2003, Archives of pediatrics & adolescent medicine.

[59]  J. Kaufman,et al.  Pharmacotherapy of early-onset depression. Update and new directions. , 2000, Child and adolescent psychiatric clinics of North America.

[60]  H. Koplewicz,et al.  Adolescent depression: Controlled desipramine treatment and atypical features , 1998, Depression and anxiety.

[61]  N. Ryan,et al.  Childhood and adolescent depression: a review of the past 10 years. Part II. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[62]  T. Cooper,et al.  Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.

[63]  S. Kutcher,et al.  Response to desipramine treatment in adolescent major depression. , 1991, Psychopharmacology bulletin.

[64]  T. Cooper,et al.  Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a "fixed plasma level" design. , 1990, Psychopharmacology bulletin.

[65]  S. Preskorn,et al.  Followup of adolescents initially treated for prepubertal-onset major depressive disorder with imipramine. , 1990, Psychopharmacology bulletin.

[66]  R. Goetz,et al.  Imipramine in prepubertal major depressive disorders. , 1987, Archives of general psychiatry.

[67]  G. Nissen.  Treatment for depression in children and adolescents. , 1986, Psychopathology.

[68]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .